Progesterone is necessary to induce the progesterone receptors. When no binding hormone is present the carboxyl terminal inhibits transcription. Binding to a hormone induces a structural change that removes the inhibitory action. Progesterone antagonists prevent the structural reconfiguration.
After progesterone binds to the receptor, restructuring with dimerization follows and the complex enters the nucleus and binds to DNA. There transcription takes place, resulting in formation of messenger RNA that is translated by ribosomes to produce specific proteins.
In common with other steroid receptors, the progesterone receptor has a N-terminal regulatory domain, a DNA binding domain, a hinge section, and a C-terminal ligand binding domain. A special transcription activation function (TAF), called TAF-3, is present in the progesterone receptor-B, in a B-upstream segment (BUS) at the amino acid terminal. This segment is not present in the receptor-A.
As demonstrated in progesterone receptor-deficient mice, the physiological effects of progesterone depend completely on the presence of the human progesterone receptor (hPR), a member of the steroid-receptor superfamily of nuclear receptors. The single-copy human (hPR) gene uses separate promoters and translational start sites to produce two isoforms, hPR-A and -B, which are identical except for an additional 165 amino acids present only in the N terminus of hPR-B. Although hPR-B shares many important structural domains as hPR-A, they are in fact two functionally distinct transcription factors, mediating their own response genes and physiological effects with little overlap. Selective ablation of PR-A in a mouse model, resulting in exclusive production of PR-B, unexpectedly revealed that PR-B contributes to, rather than inhibits, epithelial cell proliferation both in response to estrogen alone and in the presence of progesterone and estrogen. These results suggest that in the uterus, the PR-A isoform is necessary to oppose estrogen-induced proliferation as well as PR-B-dependent proliferation.
Six variable sites, including four polymorphisms and five common haplotypes have been identified in the human PR gene . One promoter region polymorphism, +331G/A, creates a unique transcription start site. Biochemical assays showed that the +331G/A polymorphism increases transcription of the PR gene, favoring production of hPR-B in an Ishikawa endometrial cancer cell line.
Several studies have now shown no association between progesterone receptor gene +331G/A polymorphisms and breast or endometrial cancers. However, these follow-up studies lacked the sample size and statistical power to make any definitive conclusions, due to the rarity of the +331A SNP. It is currently unknown which if any polymorphisms in this receptor is of significance to cancer.
^Feigelson HS, Rodriguez C, Jacobs EJ, Diver WR, Thun MJ, Calle EE (2004). "No association between the progesterone receptor gene +331G/A polymorphism and breast cancer". Cancer Epidemiol. Biomarkers Prev.13 (6): 1084–5. PMID15184270.
^Dossus L, Canzian F, Kaaks R, Boumertit A, Weiderpass E (2006). "No association between progesterone receptor gene +331G/A polymorphism and endometrial cancer". Cancer Epidemiol. Biomarkers Prev.15 (7): 1415–6. doi:10.1158/1055-9965.EPI-06-0215. PMID16835347.
^Zhang XL, Zhang D, Michel FJ, Blum JL, Simmen FA, Simmen RC (June 2003). "Selective interactions of Kruppel-like factor 9/basic transcription element-binding protein with progesterone receptor isoforms A and B determine transcriptional activity of progesterone-responsive genes in endometrial epithelial cells". J. Biol. Chem.278 (24): 21474–82. doi:10.1074/jbc.M212098200. PMID12672823.
Guiochon-Mantel A, Loosfelt H, Lescop P, et al. (1989). "Mechanisms of nuclear localization of the progesterone receptor: evidence for interaction between monomers". Cell57 (7): 1147–54. doi:10.1016/0092-8674(89)90052-4. PMID2736623.
Oñate SA, Tsai SY, Tsai MJ, O'Malley BW (1995). "Sequence and characterization of a coactivator for the steroid hormone receptor superfamily". Science270 (5240): 1354–7. doi:10.1126/science.270.5240.1354. PMID7481822.
Zhang Y, Beck CA, Poletti A, et al. (1995). "Identification of phosphorylation sites unique to the B form of human progesterone receptor. In vitro phosphorylation by casein kinase II". J. Biol. Chem.269 (49): 31034–40. PMID7983041.
Mansour I, Reznikoff-Etievant MF, Netter A (1995). "No evidence for the expression of the progesterone receptor on peripheral blood lymphocytes during pregnancy". Hum. Reprod.9 (8): 1546–9. PMID7989520.
Kalkhoven E, Wissink S, van der Saag PT, van der Burg B (1996). "Negative interaction between the RelA(p65) subunit of NF-kappaB and the progesterone receptor". J. Biol. Chem.271 (11): 6217–24. doi:10.1074/jbc.271.11.6217. PMID8626413.
Wang JD, Zhu JB, Fu Y, et al. (1996). "Progesterone receptor immunoreactivity at the maternofetal interface of first trimester pregnancy: a study of the trophoblast population". Hum. Reprod.11 (2): 413–9. PMID8671234.
Thénot S, Henriquet C, Rochefort H, Cavaillès V (1997). "Differential interaction of nuclear receptors with the putative human transcriptional coactivator hTIF1". J. Biol. Chem.272 (18): 12062–8. doi:10.1074/jbc.272.18.12062. PMID9115274.
Shanker YG, Sharma SC, Rao AJ (1997). "Expression of progesterone receptor mRNA in the first trimester human placenta". Biochem. Mol. Biol. Int.42 (6): 1235–40. PMID9305541.
Richer JK, Lange CA, Wierman AM, et al. (1998). "Progesterone receptor variants found in breast cells repress transcription by wild-type receptors". Breast Cancer Res. Treat.48 (3): 231–41. doi:10.1023/A:1005941117247. PMID9598870.
Williams SP, Sigler PB (1998). "Atomic structure of progesterone complexed with its receptor". Nature393 (6683): 392–6. doi:10.1038/30775. PMID9620806.